Urticaria is a classic cutaneous manifestation of drug allergy considered like the second most frequent drug eruption after maculopapular exanthemas. Most of the time drugs are responsible of acute urticaria lasting less than 24 hours. The mechanisms of these acute urticarial reactions are multiple, mostly related to an IgE-induced reaction. Nevertheless, some drugs can induce immune complexes and activate the complement cascade (sickness disease). Others may directly release mast cells mediators or activate complement by non immunologic mechanisms in the absence of antibody. In every case, these drugs are unable to generate urticaria during more than 6 weeks, time allowed for calling a chronic urticaria. However drugs like nonsteroidal anti-inflammatory drugs and acetysalicylic acid can, by a pharmacologic mechanism, exacerbate or trigger chronic urticaria. Angiotensin-converting enzyme inhibitors, by a defect of degradation of bradykinin, may also induced angioedemas. In this context, if an allergologic investigation is useful in the exploration of acute urticaria, it seems useless for chronic urticaria.
Download full-text PDF |
Source |
---|
Cureus
December 2024
Dermatology, C.U. Shah Medical College and Hospital, Surendranagar, IND.
Introduction Chronic urticaria is a transient cutaneous disorder that waxes and wanes swiftly but, due to its periodic episodes, declines the quality of life of the affected individuals. It is of two types: chronic spontaneous or idiopathic and chronic-induced urticaria. Urticaria can have many different causes, but one of the most common causes of chronic idiopathic urticaria (CIU) is autoimmune.
View Article and Find Full Text PDFAllergol Int
January 2025
Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.
Allergy
January 2025
St John's Institute of Dermatology, Guy's Hospital, London, UK.
Background: This study compared the therapeutic equivalence of CT-P39 (an omalizumab biosimilar) and EU-approved reference omalizumab (ref-OMA) in patients with chronic spontaneous urticaria.
Methods: This double-blind, randomized, active-controlled Phase 3 study (NCT04426890) included two 12-week treatment periods (TPs). In TP1, patients received CT-P39 300 mg, ref-OMA 300 mg, CT-P39 150 mg, or ref-OMA 150 mg.
Int J Dermatol
January 2025
Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Rev Paul Pediatr
January 2025
Universidade Federal de São Paulo, São Paulo, SP, Brazil.
Objective: This paper aims to review the efficacy and safety of current chronic urticaria (CU) treatment in children and the existing patient-reported outcome measures (PROMs) used in this age group.
Data Source: Since there are few studies of CU in children, the authors performed a non-systematic review of published articles in English, Spanish, and Portuguese in the PubMed database in the last decade. Keywords used were (antihistamines OR omalizumab OR cyclosporine OR treatment) AND (chronic urticaria) AND (children OR adolescents).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!